Polyrizon Ltd. PLRZ 深 沪
等待开盘 05-15 09:30:00 美东时间
15.02
-0.160
-1.05%
华盛通- 最 高16.3175
- 今 开15.50
- 成交量 6.86万股
- 最 低 14.61
- 昨 收 15.18
- 总市值 2963.19万
- 52周最高 18.20
- 市盈率 静 --
- 换手率 3.48%
- 52周最低 2.88
- 委 比 -6.38%
- 总股本 197.28万
- 历史最高 7200.00
- 量 比 1.28
- 振 幅 11.25%
- 历史最低 4.80
- 每 手 1
- 风险率 4.48%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Pulse Equity: Emerging Outbreaks - Polyrizon's Approach to Broad and Rapidly Deployable Protection
In light of the growing challenges posed by emerging respiratory threats, including recent Hantavirus, Polyrizon is advancing a biophysical barrier technology that may offer immediate, non-s...
05-11 19:25
Polyrizon Expands U.S. Patent Claims for Intranasal Drug Delivery Platform
Polyrizon Ltd. ( ($PLRZ) ) has shared an update. On May 4, 2026, Polyrizon Ltd....
05-04 21:17
Polyrizon expands U.S. patent claims for intranasal drug delivery platform
Polyrizon expands U.S. patent claims for intranasal drug delivery platform Polyrizon submitted amended claims in a U.S. patent application to broaden protection for its intranasal drug-delivery hydrogel platform beyond core mucoadhesive composition to cover drug-delivery systems and methods of use.
05-04 20:54
Polyrizon Files European Patent Application For Trap & Target Platform Technology
This application focuses exclusively on protecting the Company's advanced intranasal drug delivery system, which is designed to enhance the effectiveness of medications by increasing their residence time and ensuring
04-27 21:29
Polyrizon Announces Filing of European Patent Application for Its Breakthrough Drug Delivery Platform
Polyrizon Ltd. filed a divisional patent application with the Europe Patent Office for its Trap & Target (T&T) platform technology, focusing on its advanced intranasal drug delivery system. The T&T platform aims to enhance drug effectiveness by increasing residence time and improving bioavailability, while preventing dripping and utilizing biodegradable components. It is versatile for various drug types and therapeutic applications, such as treat...
04-27 13:28
Polyrizon Announces Direct Offering And Concurrent Private Placement With Unnamed Institutional Investor For A Combined ~$3.5M, Transactions To Close April 8
The transactions consisted of the sale of 388,888 Units (or Pre-Funded Units), each consisting of one (1) Ordinary Share (or one (1) Pre-Funded Warrant to purchase one (1) Ordinary Share) and one (1) Common Warrant to
04-07 20:05
Polyrizon Ltd. Announces $3.5 Million Registered Direct Offering and Private Placement
Polyrizon Ltd. announced it has entered into definitive agreements with a single institutional investor to sell its Ordinary Shares and pre-funded warrants in a registered direct offering and concurrent private placement, raising approximately $3.5 million. The transactions include the sale of 388,888 Units, each consisting of one Ordinary Share or Pre-Funded Warrant and one Common Warrant. The offering is expected to close on April 8, 2026, with...
04-07 12:00
Polyrizon Provides 2025 and Recent Highlights
Polyrizon Ltd. reported a strong end to 2025 with $17.5 million in cash, a debt-free balance sheet, and significant progress in its nasal spray programs. Key achievements include successful FDA meetings for its allergy and viral blockers, GMP manufacturing for clinical trials, and positive preclinical results for its hydrogel technology. The company also announced branding for its allergy blocker (NASARIX™) and strategic investments in high-growt...
03-26 13:23
Polyrizon Signs Memorandum Of Understanding To Acquire Up To 20% Of Colugo Systems For $6M In Potential Cash/Share Issuance Combination
Under the terms of the MOU, two shareholders will sell to Polyrizon approximately 20% of the outstanding share capital of Colugo on a fully-diluted basis. The aggregate purchase price for the Colugo shares is up to US
03-24 20:53
Polyrizon Signs Deal With Contract Research Organization To Carry Out Package Of Preclinical Biocompatibility Studies In Accordance With ISO 10993 Standards, GLP Requirements
Polyrizon Ltd. (Nasdaq: PLRZ) ("Polyrizon" or the "Company"), a pre-clinical-stage biotechnology company developing intranasal administrated solutions, today announced the signing of an agreement with a leading global
03-17 20:27
